In line with our previous results, co-treatment of IL-4-stimulated BMDMs with Pam3 resulted in significantly larger tumors when mixed with B16 melanoma cells relative to IL-4 alone (Fig. 5h). This evidence concerns the gene IL4 and melanoma.